Iritec

Irinotecan Hydrochloride Trihydrate, the active ingredient in Iritec, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Iritec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Iritec is a chemotherapy agent that targets the topoisomerase I pathway in solid tumours, primarily colorectal cancer.

- Metastatic colorectal cancer: improves overall survival when used in standard regimens. - Advanced colorectal cancer: provides disease control in patients who have progressed on prior therapy. - Combination therapy for colorectal cancer: enhances the efficacy of fluoropyrimidine‑based regimens.

Iritec may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with anti‑emetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness. - Anemia: decreased red blood cell count.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent treatment. - Severe colitis or intestinal perforation. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or liver failure. - Pulmonary toxicity: interstitial pneumonitis. - Hemorrhagic cystitis: bladder inflammation with bleeding.

Before initiating Iritec, clinicians should consider several safety measures.

- Baseline blood counts: assess neutrophil and platelet levels. - Liver function monitoring: evaluate transaminases and bilirubin. - Renal function assessment: check creatinine clearance. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Concomitant infections: treat active infections before chemotherapy. - Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Iritec can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Live vaccines: may cause uncontrolled infection.

Moderate Interactions (Monitor Closely): - Other myelosuppressive agents: cumulative bone‑marrow suppression. - Anticoagulants (warfarin, DOACs): heightened bleeding risk. - Antidiarrheal agents (loperamide): may mask early signs of severe diarrhea. - Proton pump inhibitors: possible alteration of gastric pH affecting absorption of oral supportive drugs.